These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3659037)

  • 21. [Renaissance of estrogen therapy in advanced prostate carcinoma?].
    Smith PH; Robinson MR
    Urologe A; 1995 Sep; 34(5):393-7. PubMed ID: 7483156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current management of prostatic carcinoma.
    Bahnson RR; Catalona WJ
    Prim Care; 1985 Dec; 12(4):795-813. PubMed ID: 3909178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ketoconazole therapy for hormonally refractive metastatic prostate cancer.
    Johnson DE; Babaian RJ; von Eschenbach AC; Wishnow KI; Tenney D
    Urology; 1988 Feb; 31(2):132-4. PubMed ID: 3341098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].
    Bruchovsky N; Goldenberg SL; Rennie PS; Gleave M
    Urologe A; 1995 Sep; 34(5):389-92. PubMed ID: 7483155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of hormone-resistant prostate cancer.
    Gibbons RP
    Prog Clin Biol Res; 1989; 303():337-45. PubMed ID: 2674995
    [No Abstract]   [Full Text] [Related]  

  • 26. [Castration in the treatment of locally advanced or metastatic prostate cancer].
    Mongiat-Artus P
    Rev Prat; 2013 Apr; 63(4):509-10. PubMed ID: 23682480
    [No Abstract]   [Full Text] [Related]  

  • 27. [Advanced prostatic carcinoma--which hormone therapy when?].
    Studer UE
    Urologe A; 1995 Sep; 34(5):361-6. PubMed ID: 7483151
    [No Abstract]   [Full Text] [Related]  

  • 28. Secondary hormonal therapy.
    Smith DC
    Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
    Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
    Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Complex treatment of prostate cancer patients].
    Sviridova TV; Dunchik VN; Mardynskiĭ IuS; Tsodikova LB
    Urol Nefrol (Mosk); 1984; (2):9-13. PubMed ID: 6719653
    [No Abstract]   [Full Text] [Related]  

  • 31. Prostate cancer: metastatic.
    Michaelson D; Talcott J; Smith M
    Clin Evid; 2002 Jun; (7):804-11. PubMed ID: 12230706
    [No Abstract]   [Full Text] [Related]  

  • 32. Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy.
    Cox RA; Sundar S
    Br J Cancer; 2008 Jan; 98(1):238-9. PubMed ID: 18182981
    [No Abstract]   [Full Text] [Related]  

  • 33. [Modern approaches to treating locally-advanced and disseminated prostate cancer].
    Veliev EI
    Ter Arkh; 2002; 74(10):67-70. PubMed ID: 12469638
    [No Abstract]   [Full Text] [Related]  

  • 34. Prostate cancer: improving the therapeutic index.
    Scher HI
    Semin Oncol; 1994 Oct; 21(5):688-93. PubMed ID: 7524157
    [No Abstract]   [Full Text] [Related]  

  • 35. [Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status].
    Stege R; Carlström K; Hedlund PO; Pousette A; von Schoultz B; Henriksson P
    Urologe A; 1995 Sep; 34(5):398-403. PubMed ID: 7483157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population based study of hormonal therapy and survival in men with metastatic prostate cancer.
    Lu-Yao G; Moore DF; Oleynick JU; DiPaola RS; Yao SL
    J Urol; 2007 Feb; 177(2):535-9. PubMed ID: 17222628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hormonal implications in the development and treatment of prostate cancer.
    Ip C; Hall SJ
    Endocrinol Metab Clin North Am; 2007 Jun; 36(2):421-34. PubMed ID: 17543727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re: Additional treatment for pT3 prostate cancer: now, later or never.
    Pitts WR
    BJU Int; 2008 Jul; 102(1):133; author reply 133-4. PubMed ID: 18564235
    [No Abstract]   [Full Text] [Related]  

  • 39. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88.
    Walsh PC
    J Urol; 2005 Sep; 174(3):929. PubMed ID: 16093992
    [No Abstract]   [Full Text] [Related]  

  • 40. Endocrine therapy for prostate cancer: recent developments and current status.
    Schröder FH
    Br J Urol; 1993 Jun; 71(6):633-40. PubMed ID: 8343887
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.